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Abstract
COVALENT BINDING AND OTHER MECHANISMS OF PRIMAQUINE TOXICITY
by
Lucille S. K. Chau Yau

A dose-dependent covalent binding of primaquine to mouse liver
microsomal protein was found in both in vitro and in vivo studies.
The binding in vitro was linear during the first 90 minutes of incu
bation and dependent on the concentration of mouse liver microsomal
protein.

The in vitro covalent binding was markedly enhanced by co

factors.

Pretreatment of mice with phenobarbital, a cytochrome P450

inducer, increased the microsomal cytochrome P450 content and the in
vitro covalent binding significantly.

Binding was markedly inhibited

when microsomal metabolism inhibitors (SK&F-525A, metyrapone and
piperonyl butoxide), and sulfhydryl-contai ni ng compounds were added
to the incubation system.

Conversely, the inhibitory effect of

inhibitors was not shown on in vivo binding; also induction with pheno
barbi tal decreased the extent of covalent bindi ng in vivo.

These

findings pointed to the possibility that the extent of in vivo forma
tion of metabolites which can bind covalently may be limited.

However,

injection of PQ (80 mg/Kg) into mice decreased the glutathione content
of liver and erythrocytes, possibly through the formation of reactive
metabolites.

The NADPH-induced peroxidation of lipid of mouse mi crosomes and
human erythrocyte membranes were markedly inhibited by PQ and 5H6DPQ
(a PQ derivative), respectively.

In contrast, PQ and its derivatives

enhanced the NADPH-i nduced peroxidation of the lipids of intact
erythrocytes.
A significant amount of PQ metabolite(s) (formed by the mouse
liver microsomal cofactor system) was bound covalently to the total
protein of both normal and G6PD-deficient erythrocytes..

The net bind

ing to the protein of G6PD-defi ci ent red cells was significantly
greater than that to normal cells.

A measurable amount of covalent

binding of PQ metabolite(s) to human hemoglobin was also demonstrated.
A small but significant amount of PQ metabolite(s) was also bound to
human erythrocyte membrane protein.

PQ and its derivatives decreased

the amount of measurable sulfhydryl groups of G6PD-defi ci ent human
erythrocyte membranes significantly but had no effect on the -SH
groups of normal cell membranes.

These results suggest that covalent

binding of PQ metabolite(s) to human erythrocyte total protein and
membrane protein as well as to hemoglobin may play an important role
in hemolysis, particularly after cellular GSH and membrane sulfhydryl
groups are depleted.
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CHAPTER 1:

GENERAL INTRODUCTION

Glucose-6-Phosphate Dehydrogenase Deficiency
The occurrence of a deficiency of the enzyme glucose-6-phosphate
dehydrogenase (G6PD) in human erythrocytes was discovered during
investigations in Chicago (Carson et aj_. , 1956) of acute hemolytic
anemia which occurred in about 10% of American Negroes after adminis
tration of the 6-methoxy-8-ami noqui noli ne antimalarial drug, prima
quine (PQ).

This was 30 years after the first reported case of

hemolysis induced by the related drug, pamaquine.
G6PD is the first enzyme in the pentose phosphate pathway (PPP).
It catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone by NADP, which is reduced to NADPH.
regulatory step of the PPP.

This is the main

Approximately 10% of glucose-6-phosphate

is metabolized by the PPP in normal, unstressed erythrocytes, while
the other 90% is metabolized by the Embden-Meyerhof pathway of
anaerobic glycolysis (Murphy, 1960).
G6PD-deficient erythrocytes have a diminished G6PD activity and
other related metabolic abnormalities (Tarlov, et al., 1962; Carson and
Frischer, 1966; Beutier, 1978):
phosphate pathway:

(1) Abnormalities of the pentose

pentose phosphate metabolism is deficient; NADPH

regeneration capacity is impaired; reduced glutatione (GSH) content
is reduced and GSH is more vulnerable to oxidation; glutathione
reductase activity is increased due to a compensatory mechanism or a
younger erythrocyte population; 0^ consunption is reduced and rate of
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glucose utilization is diminished; lipid content is decreased; rate of
methemoglobin reduction is diminished; methemoglobinemia is increased
and cells are more susceptible to Heinz body formation; (2) Abnormali
ties of Embden-Meyerhof Pathway:
decreased NADPH/NADP ratio

increased aldolase activity;

and fall in ATP content in vitro;

(3) Diminished catalase activity.
Besides the biochemical abnormalities in G6PD-deficient
erythrocytes, Afolayan (1979) found that the reactivity of lipids and
proteins of normal red cell (G6PD A) membranes, preincubated with PQ
or chloroquine with tri nitrobenzene sulphonate, is less than that of
G6PD-defi ci ent red cell (G6PD A-) membranes.

The fluorescence studies

in the presence of PQ or chloroquine also suggested a possible
structure difference between the two types of ghosts.
The severity of hemolysis that occurs after ingestion of certain
hemolytic drugs, chemicals, or plants is influenced by the concentra
tion of drug in the blood; viral and bacterial infections; diabetic
acidosis; hypoglycemia of the newborn; age of the erythrocytes and
schedule of drug administration (Tarlov et aj_., 1962).
The deficiency in G6PD activity may be caused by decreased
synthesis of enzyme molecules, reduced stability of enzyme molecules,
decreased catalytic activity, the absence of activators or coenzymes
essential for G6PD activity, the presence of inhibitors, or a combina
tion of two or more of these mechanisms (Tarlov et_ al. , 1962; Carson

and Frischer, 1966; Beutler, 1969, 1982).
Until 1982, about 147 variants of G6PD have been characterized
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(Beutler, 1982) according to the criteria set forth by the World
Health Organization scientific group:

(1) red cell G6PD activity; (2)

electrophoretic mobility in different buffers; (3) the Michaelis
constants for its substrates, glucose-6-phosphate and NADP; (4)
capacity to utilize 2-deoxy glucose-6-phosphate, galactose-6phosphate, and deamino NADP and NAD; (5) heat lability; and (6) pH
optimum.
G6PD B is the normal enzyme and is the most common type with a
half life of 63 days.

The most common types of G6PD deficient

variants found in human erythrocytes are G6PD A, with 84% of normal
enzyme activity; A-, with 5 to 15% of normal enzyme activity; Canton,
with 0 to 5% of normal enzyme activity; and Mediterranean, with almost
no enzyme activity in mature erythrocytes (Haut, 1980).
G6PD deficiency in the Caucasian and Oriental is more severe than
that in the Negro.

Hemolysis can be produced by very mild oxidant

stress in patients with the Mediterranean type variant.

A small

number of G6PD-deficient subjects have a very rare variant.

They show

the clinical picture of nonspherocytic congenital hemolytic anemia,
but they experience hemolytic anemia in the absence of exposure to any
stress (Beutler, 1969; Tarlov et al., 1962).
G6PD-deficiency has a world-wide distribution.
is highest in tropical and semi-tropical areas.

The incidence

The geographic

distribution of this most common red cell enzyme deficiency tends to
parallel the occurence of Plasmodium falcipariun malaria.

Moreover,

G6PD-deficient erythrocytes are less frequently parasitized than
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normal red cells in vitro (Luzzatto et al., 1969).

The frequency of

the deficient gene is approximately 10% among American Negroes
(Hockwald et al_. , 1952), 5.5% among Southern Chinese (Chan et al. ,
1964) and a high incidence among Southern Mediterranean people
(Szeinberg et jil_., 1958).

Seldom are cases reported from Northern

Europe.
The geographic distribution of G6PD-deficiency suggests an
selective evolutionary advantage against malaria (Allison and Clyde,
1961).

GSH (Trager, 1941; Friedman, 1979) and the PPP (Trager, 1941)

are essential for optimum growth of malaria parasites.

The low GSH

content and the diminished PPP activity of G6PD-deficient erythrocytes
are not adequate for survival of the invading parasites.'When sera.
collected from normal subjects at certain times after ingestion of a
meal of fava beans, were added to cultures of P. falciparum in normal,
G6PD-deficient, or 3-thalassemia trait red cells, Friedman (1983)
discovered that some sera were inhibitory to parasites in variant
cells but not to those in normal red cells.
The recent study by Luzzatto et ll- (1983) indicated that
Plasmodiun falciparum invades G6PD-defi cient erythrocytes
(Mediterranean variant) normally in culture but maturation of
intracellular parasites is delayed and impaired, especially if the red
cells are under oxidative stress.

An adaptive change on the part of

the parasites has been found since the invading parasites have a
normal behaviour in the next cycle in G6PD-defi ci ent erythrocytes.
Childs et aj_. (1 958) reported that the structural gene for
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G6PD-deficiency is sex-linked,

The gene is located on the X-

chromosome close to the locus for color blindness (Adam, 1961;
Sim’s cal co and Filippi, 1964).

The gene can be fully expressed in

hemizygous male subjects (XY) and rarely in homozygous females (XX).
Heterozygous female subjects (XX) have one cell population with normal
enzyme activity and another population with deficient activity
(Beutler, 1982).

Therefore, the phenotype activity is either normal,

intermediate, or low as in homozygotes or hemizygotes (Tarlov et al. ,
1962).

Only one of the two X chromosomes present in each somatic cell

of the female is active, the other one being inactivated (Lyon
hypothesis).
Most G6PD-deficient individuals have no overt symptoms under
normal conditions since there is enough G6PD activity to protect the
cells in the normal physiologic state,

However, when these subjects

are under oxidant stress (exposed to certain drugs, chemicals or
plants), this deficiency increases the susceptibility of the red cells
to destruction.

Primaquine Metabolism
Primaquine (6-methoxy-8-(4-ami no-1-methylbutyl ami no)quinoline,
PQ) is an antimalarial drug.

PQ and other 8-ami noquinolines have

been shown to be toxic to some sensitive individuals with G6PD
deficient erythrocytes.

Despite the widespread use of the drug, the

metabolism of PQ is not well understood.
Some possibilities were suggested by the early work on the
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metabolism of pamaquine by Brodie and Udenfriend (1950).

From studies

in dogs, they speculated that there was formation of a 5-hydroxy
metabolite which reversibly produced a quinonimine capable of
oxidizing hemoglobi n to methemoglobi n.

Josephson et aj_. (1951)

isolated a quinone of pamaquine formed by chickens and suggested that
this metabolite may be the active agent against the malaria parasites.
In early studies in man, Zubrod (1948) observed that the highest
plasma concentration of unmetabolized primaquine in patients was
reached after 6 hours, then fell rapidly to virtually zero after 24
hours.

Other investigators also found that PQ, pamaquine, and

pentaquine underwent rapid biotransformation in the rhesus monkey
(Hughes and Schmidt, 1950; Smith, 1956).

Only relatively small amounts

of the unmetabolized PQ were found in the urine (Smith, 1956).

The

plasma level of metabolites of PQ and pentaquine exceeded that of the
parent compounds (Hughes and Schmidt, 1950).
More recently Baty et aj_. (1975) found rapid metabolism of PQ in
man by measuring the PQ level in blood and the uri nary excretion after
oral administration of PQ to male subjects.
cells but not in plasma extracts.

They found PQ in red

Using gas chromatography and mass

spectrometry, they found that PQ underwent N-dealkylation to form a 6methoxy-8-ami noqui noli ne derivative.
In studying the tissue distribution of PQ in rat, Holbrook et al.
(1981) showed that concentration of PQ metabolites exceeded that of PQ
itself and that unmetabolized PQ had a relatively short half-life, 4.0
hour in lung, 1.7 - 1.9 hour in blood, spleen, kidney and heart; and
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1.2 hour in liver.

The tissue concentrations of unmetabolized PQ at 3

hours after PQ injection were in the order:
liver > heart > brain > blood.

lung > kidney, spleen,
3
They could not demonstrate any FI-

labeled metabolite with the quinoline structure in either extracts of
rat tissues or after the in vitro incubation of PQ with rat hepatic
microsomes in the presence of NADPFI under air.
The investigation of Strother et a/L (1981) in dogs given PQ
indicated that the PQ is metabolized rapidly or distributed from the
blood to other parts of the body.

These investigators observed that

four or five metabolites of PQ are present in the urine of dog within
five hours after injection, some of which cause methemoglobi n forma
tion in dog and normal or G6PD-deficient human erythrocytes.

In these

experiments, using thin-layer chromatography and comparing with model
metabolites, Strother et aj_.

(1981) identified 6-hydroxy-8-(4-amino-1-

methyl butyl ami no)qui noli ne (6FIPQ), 5-hydroxy-6-methoxy-8- (4-ami no-1methyl butyl ami no )qui noli ne (5FIPQ), and unmetabolized PQ from urinary
extracts of dogs.

There was about 46.1%, 9.5% and 19.7% of 5FIPQ, 6HPQ

and PQ, respectively.

Strother et _al_. (1983) identified unmetabolized

PQ and 5,6-di hydroxy-8-(4-ami no-l-methyl butyl ami no )qui noline (5FI6DPQ)
from an incubation mixture of PQ and mouse liver microsomes in the
presence of an NADPFI-generati ng system.
Recently, Baker ^t aj_. (1982) have identified a carboxylic acid
metabolite (8-(3-carboxy-l-methylpropylamino)-6-methoxyquinoli ne) in
plasma from rat after PQ intravenous injection using high-performance
liquid chromatographic, gas chromatographic, and mass spectral
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methods.

They also found that the concentration of metabolites is

higher than that of PQ itself in the plasma except for the first few
minutes after PQ injection.
Magon et a1_. (1981) reported that the various hemolytic responses
among G6PD-deficient subjects to PQ and other hemolytic drugs may be
due to the variation of hydroxylation of these compounds via the
cytochrome-P450 mixed function oxidase system.
These findings suggest the possibility that metabolites of PQ are
responsible for the therapeutic as well as the toxic effects of PQ.
In any event, it is important to identify the structure of PQ metabolite(s) which is responsible for the antimalarial and toxic effects.
Modification of the structure of PQ and its metabolite(s) to develop a
new drug with high therapeutic index and diminished hemolytic effect
in sensitive subjects may improve malaria chemotherapy.

Mechanism of Hemolysis by Primaquine
In the decade of the 1950's, many investigators studied the
hemolytic effect of PQ on sensitive subjects.

The hemolysis was found

to be due to an intrinsic defect of the red cells of individuals
sensitive to PQ (Dern et _al_. , 1954a).

Using 51Cr-labelled PQ-

sensitive erythrocytes, Dern jit jfL (1954b) found that the acute
hemolysis after PQ administration in 9 daily doses of 30 mg base was
self-limited; the blood counts returned to normal spontaneously even
when drug administration was continued.

Except for the presence of

Heinz bodies in the red cells of sensitive subjects just before and at
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the beginning of hemolysis, Beutler et a/L (1954a) could not detect
any significant differences between normal and sensitive cells either
before or during PQ administration.

These investigators (Beutler et

C Q

al., 1 95 4b) later discovered that

Fe-labeled red cells from

sensitive individuals were insensitive to the hemolytic effect of PQ
when they were 8 to 21 days old.

However, when the age of these red

cells exceeded one-half of their life span, they were rapidly
destroyed by PQ and certain aniline derivatives.

Red cells contain a

variety of enzyme systems which catalyze a large number of metabolic
processes.

Concentrations of many enzymes and coenzymes are decreased

as the red cells become older (Ponder, 1951).

This suggested that a

deficiency in one of the enzymes in older red cells may play a role in
PQ sensitivity.

Furthermore, Dern ^t aj_. (1955) reported that PQ

sensitivity was a manifestation of a multiple drug sensitivity.
the drugs they studied had oxidant properties.
et aj_.

All

The studies of Beutler

(1955 ) indicated that PQ-sensitive erythrocytes carried on

normal glycolysis but contained only about 60% of the normal amount of
GSH.

The finding by Carson _et _a1. (1956) that the PQ-sensitive cells

were deficient in glucose-6-phosphate dehydrogenase (G6PD) activity
provided the first evidence for an explanation of these findings.

The

decreased supply of NADPH from the pentose phosphate shunt can slow
the regeneration of GSH from GSSG (Beutler, 1978).
On the basis of the previously reported studies on PQ metabolism,
Tarlov et _al. (1962) suggested that the hemolytic effect of PQ may be
due to an oxidant quinone, a degradative intermediate, which has
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anti catalase effect.

The quinone may undergo a reversible oxidation-

reduction reaction and eventually be metabolized to a quinonimine.
Cohen and Hochstein (1964) found that PQ in high concentrations
(1 mM) produced hydrogen peroxide and methemoglobin in normal erythro
cytes.

They proposed that this could be a mechanism for oxidation of

GSH and ultimately hemolysis in G6PD-deficient erythrocytes.
Internalization of the red cell membrane and formation of intracellu
lar vacuoles were also observed after incubation of normal human
erythrocytes with high concentrations of PQ by Ginn, Hochstein and
Trump (1969).

They suggested that this morphological change in the

red cell membrane led to reduction in surface area and was significant
in red cell destruction.
Following the lead of Brodie and Udenfriend (1948) with
pamaquine, Fraser and Vesell (1968) found that metabolites formed from
PQ administered to dogs produced red cell damage and hemolysis; this
was subsequently confirmed and extended by Strother et jf[.

1981).

(1975 ,

Fraser and Vesell (1968) also found that 5,6-dihydroxy

derivative of pentaquine and 5 ,6-di hydroxy-8-ami noqui noli ne were
considerably more active than PQ in oxidizing reduced glutathione and
producing methemoglobi n in both normal and G6PD-deficient human
erythrocytes.

They suggested that metabolites of PQ rather than PQ

itself may be responsible for producing the damage to the red cell.
Subsequently they (Fraser et al., 1971) also showed that these
compounds oxidized GSH more readily in an older population of G6PDdeficient cells (with low levels of G6PD) than in a younger population
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of G6PD-deficient cells (with high levels of G6PD).
Another possibi 1 ity was raised by the finding of Wittles (1970)
that modification of phospholipid metabolism in human red cell
membranes could be produced by PQ.

He suggested that this might be

another possible mechanism in drug-induced hemolysis.
The production of superoxide radicals by high concentrations of
primaquine has been recently reported by Sunmerfield and Tudhope (1978)
and confirmed by Fraser et_ a1_.

(1981).

Hydrogen peroxide formed from

the superoxide radical led to methemoglobin formation.

Again Fraser

et _al_. (1981) found that hydroxylated derivatives of PQ were much more
active than PQ in producing superoxide anion or hydrogen peroxide.
On the basis of some of the above experimental observations the
following possible events seem likely in the production of hemolysis
by PQ administration in a G6PD-deficient individual:

(1) PQ is con-

verted to reactive metabolites by the microsomal mixed-function
oxidase system; (2) superoxide radicals or hydrogen peroxide produced
by PQ metabolites or its nonenzymatic degradation products, may
mediate hemoglobin oxidation, glutathione oxidation, and oxidative
damage to the erythrocyte membrane; (3) however the glutathione
peroxidase system may protect against cell damage by peroxide at the
expense of reduced glutathione (Chance, Sies and Boveris, 1979); (4)
G6PD-deficient erythrocytes are less capable of restoring nonnal
reduced glutathione content due to the limited activity of the pentose
phosphate pathway (Carson et al. , 1956; Tarlov et aj_. , 1962); (5)
disruption of the cell membrane structure may lead to electrolyte
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leakage and imbalances across the membrane (Judah _et _al. ,1970); (6)
the damaged cells may then be eliminated by intravascular hemolysis or
removed by the reticuloendothelial system.
As will be discussed in Chapter 2, recent studies with other
drugs suggest that covalent binding of reactive metabolites may play a
significant role in many different forms of drug toxicity,

Also, as

will be discussed in Chapter 3, lipid peroxidation may be an important
factor in damage to membranes by drugs.

The investigations reported

here were undertaken in order to explore the possible role of these
two phenomena in the mechanism of the hemolytic effect of PQ in

relation to the current evidence sunmarized above.

CHAPTER 2:

COVALENT BINDING OF PRIMAQUINE TO MOUSE LIVER MICROSOMES
Introduction

Primaquine (PQ, an 8-ami noqui noli ne, has been used widely in
radically curative treatment of exoerythrocytic vivax malaria since
the 1940s.

It has long been known that after large doses (30 mg) of

PQ or i n sensitive individuals, severe hemolytic anemia, leukopenia
and methemoglobinemia may be produced.
Fraser and Vesell (1968) found that the mechanical, but not the
osmotic, fragility of G6PD-deficient erythrocytes was increased more
than that of normal erythrocytes by hydroxylated model metabolites of
pentaquine and acetanilid.

These compounds also increased the

methemoglobin content, decreased the reduced glutathione content and
decreased the NADPH/NADP ratio more markedly in G6PD-deficient red
cells than in normal cells; PQ at the same concentration was much less
active.
Many drugs and foreign compounds can be converted in the animal
body to inert or active metabolites.
drug metabolism.

The liver is the major organ of

Drugs are usually metabolized to more polar

compounds which can be more readily excreted.

However, chemically

reactive metabolites may be formed which subsequently induce severe
toxicities by uncoupling integrated biochemical processes in cells or
by combining covalently with tissue macromolecules.

Toxicities

including hemolytic anemia, methemoglobinemia, mutagenesis, cellular
necrosis, hypersensitivity reactions, blood dyscrasias, and
fetotoxicities, are known to be mediated by chemically reactive
13
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metabolites (Gillette et al., 1974).
A wide variety of chemicals with unrelated structures, such as
N-alkyl-N-nitroso compounds, ethionine, urethane, polycyclic aromatic
hydrocarbons, aromatic amines, 4-nitroquinoline N-oxide and
2-acetyl ami nofl.uorene, can be converted to alkylating, arylating agents
or reactive metabolites and react with crucial cellular macromolecules
(DNA, RNA or proteins).

The subsequent covalent interaction of these

compounds with tissue proteins may result in carcinogenesis (Miller
and Miller, 1947 , 1952 , 1966; Miller, 1970; Magee and Barnes, 1967;
Farber, 1963).
Judah et a1_. (1970) suggested that the hepatic injury caused by
some hepatotoxins might be mediated by their chemically reactive
metabolites which bind to tissue macromolecules covalently.

Since

then many investigators have found that acetaminophen as well as
phenacetin is converted to toxic metabolites by hepatic microsomal
enzymes.

The metabolites depleted hepatic reduced glutathione and

were covalently bound to tissue protein.

The severity of hepatic

necrosis paralleled the magnitude of covalent binding (Mitchell et
al. , 1975).

The hepatic toxicity of acetaminophen was enhanced by a

liver microsomal enzyme inducer (phenobarbital) and decreased by
microsomal enzyme inhibitors (piperonyl butoxide, SK&F-525A, cobaltous
chloride) (Mitchell et cil_. , 1973a, b; Jollow et al_. , 1973; Potter et
al. , 1973).

Similar effects of enzyme inducers and inhibitors on the

hepatic toxicity of carbon tetrachloride and chloroform (Judah et al. ,
197 0), acetylisoni azid; acetyl hydrazine and iproniazid (Nelson et
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al_. , 1977) have also been reported.
It seems possible that chemically reactive metabolites of PQ
could leave the liver after depletion of its reduced glutathione and
bind to red cell membrane protein covalently as do bromobenzene
metabolites to lung and heart muscle tissue proteins (Reid et al_. ,
197 3).
In the investigation we are reporting here, we have tested the
hypothesis that PQ metabolites formed by mouse liver microsomes may
bind to microsomal protein covalently.

We have also investigated the

possible modification of this binding by inducers and inhibitors of
microsomal enzymes.

The possibility that formation of these

metabolites may produce a decrease of mouse liver and erythrocyte
reduced glutathione content following administration of PQ to mice was
also studied.

Materials and Methods
Chemi cals
3
Initiated primaquine ( H-PQ), labelled in the ring system, was
obtained from New England Nuclear Corporation and recrystallized in
the laboratory with nonlabelled PQ to obtain a specific activity of
0.137 mCi/mmol.

^C-PQ was supplied by the Special Programme for

Research and Training in Tropical Diseases of the World Health Organi
zation.

It was recrystallized with nonlabelled PQ to obtain a

specific activity of 1.03 Ci/mmol.

The purity of the radioactive

compounds was greater than 90% as verified by thin layer chromatogra
phy with methanol-benzene (2:1) on silica gel (Strother et aj_. , 1981).
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Primaquine diphosphate was purchased from Aldrich Chemical Company,
Inc., Milwaukee, WI.

Nicotinamide adenine dinucleotide phosphate

(NADP), glucose-6-phosphate (G-6-P), glucose-6-phosphate dehydrogenase
(Type XII) (G6PD), 1-cysteine HC1, glutathione (reduced form), phenobarbital, hexobarbital and bovine serum albumin (Fraction V) were
obtained from Sigma Chemical Company, St. Louis, MO.

Magnesiun

chloride (MgCl^.SH^O) was supplied by J. T. Baker Chemical Company,
Phi 1lipsburg, NJ.

Beta-diethylaminoethyldiphenylpropylacetate hydro

chloride (SK&F-525A) was supplied by Smith Kline and French
Laboratories, Philadelphia, PA.

Metyrapone (MTP) was a gift obtained

from CIBA Pharmaceutical Co., Summit, NJ.; piperonyl butoxide (PPB)
was obtained from K & K Laboratories, Inc., Plainview, NY.

All other

chemicals were of highest purity available.
Preparation of Microsomes
Male Swiss-Webster mice (Simonsen Laboratory, Gilroy, CA) weigh
ing 22-27 g were given regular Purina Lab Chow and water ad 1 ibitun.
They were killed by cervical dislocation, the livers were removed
immediately, blotted on absorbent paper and placed in a volume of ice
cold 1.15% KC1-0.025 M Tris buffer, pH 7.35, equal to twice the weight
of tissue.

Microsomes were prepared in the same buffer, as described

by Peters and Strother (1971).
the method of Lowry et aj_.

The protein content was determined by

(1951) using crystalline bovine serin

albumin as the reference standard.

Cytochrome P450 content was

measured as described by Peters and Fouts (1970).
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Incubation Mixture
Initiated primaquine or 14C-PQ, in 0.25 M Tris buffer (pH 7.35),
at concentrations indicated in "Results", was incubated at 37°C with
mice liver microsomes (10 mg) and 1.0 ml of 0.25 M Tris buffer
(pH 7.35) containing an NADPH-generating system:

NADP (4 ymol),

G6P (25 ymol), MgCl^ (30 ymol), and G6PD (2 units),

Control flasks

received 1.0 ml of 0.25 M Tris buffer (pH 7.35) only.

The fi nal

volume of incubation mixture was brought to 5.0 ml with 1.15% KC10.025 M Tris buffer (pH 7.35) and distilled water.

The reactions were

carried out under air in a Dubnoff shaking incubator and were stopped
by adding 1.0 ml of 10% trichloroacetic acid (TCA) at the desired
In some experiments, SK&F-525A, MTP, PPB, 1-cysteine HC1 or

time.

reduced glutathione (Tredger jit a]_. , 1981) at concentrations indi
cated in "Results", was added to the incubation mixture to study their
effects on covalent binding of PQ to mice liver microsomes.
In some studies, microsomes were prepared from mice pretreated in
several ways.

With phenobarbi tal (60 mg/Kg i. p. twice daily in normal

saline for 3 days) the mice were killed 24 hours after the last dose).
SK&F-525A (50 mg/Kg i.p. in normal saline) was administered 40 minutes
before sacrifice (Cook et ^1_. , 1954) while PPB (1 ,360 mg/Kg i.p. in
corn oil) was given 30 minutes before sacrifice (Mitchell et al. ,
1973a).

Control mice received normal saline or corn oil for similar

peri ods.
Determination of Covalent Binding of PQ to Mice Liver Microsomes
The incubation mixtures were transferred to 13 ml centrifuge
tubes and centrifuged at 500 x g (International Refrigerated Centri-
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fuge. Model PR6) for 15 minutes at room temperature.

The supernatant

was discarded, and the protein precipitate was resuspended in 3.0 ml
of 10% TCA and mixed on a Vortex shaker for 3 minutes.

The tubes were

centrifuged again at 500 x g for 10 minutes, and the protein pellets
were washed again with 3.0 ml 10% TCA.

The protein was then

resuspended in 2 ml 80% methanol, mixed for 3 minutes, centrifuged at
1000 x g for 10 minutes at room temperature and the supernatant
discarded.

This extraction was repeated until no further radioactiv

ity could be removed (Jollow et aj_. , 1973).

In our experiments, we

routinely extracted the precipitated protein 9 times with methanol
even though 6 to 7 extractions were sufficient to remove all the
reversibly bound radiolabel.

The extracted microsomal protein was

dissolved in 1.0 ml (IN NaOH) and an aliquot of 20 yl was added to
10.0 ml Cytoscint scintillation cocktail (West Chem Products, San
Diego, CA) and counted in a Beckman LS-250 scintillation counter for
radioactivity.

To ensure that the radiolabel was bound to microsomal

protein and not to lipid, some samples were extracted 3 times with 2
ml hexane before extracting with 80% methanol.
In vivo Covalent Binding
Mice were sacrificed 60 minutes after receiving varying doses of

3H-PQ or 14 C-PQ and microsomes were prepared as in the i n vitro
studies.

To 1.0 ml of each microsome homogenate, 2.0 ml of 10% TCA

was added to precipitate the protein.

The protein pellet was washed

twice with 10% TCA and extracted with 80% methanol for 9 times as
described above.

An aliquot of 100 yl was counted for radioactivity.

In other experiments, covalent binding of PQ to microsomes from mice

19
pretreated with phenobarbital, SK&F-525A, and PPB as described above
were also studied.
Primaquine Effects on Tissue Glutathione Levels
Mice were injected with PQ (80 mg/Kg, i.p.) and sacrificed by
cervical dislocation at various times after PQ administration.

Blood

was collected by cardiac puncture with heparin as anticoagulant.
blood was centrifuged at 1000 x g for 15 minutes.

The

An aliquot of the

packed erythrocytes was transferred to a centrifuge tube and lysed
with 10 times its volume of distilled water.

Five percent trichloro

acetic acid--0.02 M disodiun ethylenedi ami netetraaceti c acid solution
(TCA-EDTA) in a volime equal to that of the original red cells was
added.

Livers were removed from the mice inmediately after cervical

dislocation, rinsed in ice cold normal saline, blotted and weighed
before transferring to homogenization tubes.

A sufficient volume of

TCA-EDTA was added to the liver to give a 20% w/v homogenate.

The

tissue was homogenized using a glass mortar and a motor driven teflon
pestle.

The homogenates and lysed red blood cells in TCA-EDTA were

centrifuged at 1000 x g for 15 minutes, 0.4 ml of the protein free
supernatant was mixed with 4.55 ml of a 0.01 M sodium phosphate
buffer, pH 8.0.
fiIter paper.

The blood samples were filtered through Whatman No. 1
To each solution, 0.05 ml of 0.01 M 5,5‘-dithiobis-(2-

nitrobenzoic acid( (DTNB, Ellman's reagent) in absolute methanol was
added and absorbance of the resultant yellow colored solution against
a reagent blank was determined in a Gilford spectrophotometer at 412 nm
within 2 minutes (Sedlak and Lindsay, 1968; Olson etaj_., 1980).
Control values were also obtained when no PQ was administered.

Data
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were expressed as percentage of the control values.

Glutathione

(reduced form) was used as the reference standard.
Statistics
Data were expressed as mean ± S.E.M.

The significance of the

differences between means was determined by Students' t-test.

Statis-

tical differences were considered to be significant with p < 0.05.

Results
As can be seen in Figure 1, considerable covalent binding of
tritiated compounds to mouse liver microsomes occurred when they were
incubated with ^H-PQ.

The reaction was linear for 90 minutes with or

without the presence of an NADPH-generating cofactor system.

The

amount of binding in the absence of cofactors was subtracted from
that in the presence of cofactors to provide the net covalent binding
probably attributable to metabolite(s).

There was a steady and highly

significant increase in net binding of tritiated metabolites during
the first 90 minutes of the incubation; the net binding began to
decline slowly after 150 minutes of incubation,

In the absence of

cofactors, PQ itself or spontaneous breakdown products of PQ apparent
ly became bound to microsomal protein.
The amount of the net covalent binding of primaquine depended on
the concentration of mouse li ver mi crosomal protein, as shown in
Figure 2.

The net binding was linear up to a concentration of 10 mg

protein per 5 ml of incubation mixture and then decreased with 20 mg
protein per 5 ml.

Therefore, in studying the binding reactions, we
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routinely used a microsomal protein concentration of 10 mg in 5 ml of
incubation mixture.
The possibility that the radioactivity in the methanol-extracted
microsomes was partially attributable to primaquine still dissolved in
lipid was tested by extracting first with hexane, a relatively
nonpolar organic solvent,

As shown in Table 1, three extractions with

hexane followed by nine extractions by 80% methanol did not alter the
3
binding of radioactive material from H-PQ to the microsomes as compared
to that found with nine extractions with 80% methanol alone.
3
The effect of the concentration of H-PQ on the extent of co
valent binding in the presence and absence of cofactors was studied.
As shown in Table 2, covalent binding occurred to a virtually similar
3
extent with or without cofactors at a H-PQ concentration of 1 mM,
whereas at low concentrations of 0.001 mM or 0.01 mM, binding was
increased significantly by the presence of the cofactors.

This

suggests that at these low concentrations of PQ the increase in cova
lently bound compounds in the presence of cofactors was most probably
due to metabolites of PQ.

As shown in Figure 3, an approximately
3
linear relationship was found when the amount of H bound to the

microsomal protein is plotted against the logarithm of the concentra
tion of PQ in the incubation mixture over the range of 0.005 to 0.05 mM.
3
On the basis of these findings a concentration of H-PQ of 0.01 mM was
used in most of the other studies reported here.
In order to further establish that the net binding was attribut
able to metabolism of PQ in the presence of the NADPH-generating
system, we studied the effects of an inducer of cytochrome P450 and
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inhibitors of its function.

Using microsomes in which the cytochrome

P450 content was increased 75% by phenobarbital pretreatment, net
covalent binding i n vitro was enhanced markedly over a wide range of
primaquine concentrations, as shown in Figure 4.

On the other hand,

when the cytochrome P450 inhibitors, SK&F-525A (0.1 mM) or metyrapone
(1 mM), were added to the incubation mixture (as described in "Methods")
the net covalent binding was inhibited almost completely (Figure 4).
3
These results indicate that the net covalent binding of H to micro
somal protein was due to metabolite(s) of primaquine produced by the
action of the microsomal mixed function oxidase in the presence of the
NADPH-generating system.
Figure 5 shows a double-reciprocal plot of net covalent binding
in vitro of H-PQ metabolite(s) to microsomes prepared from control
and phenobarbi tal pretreated mice.
determined by calculation.

The kinetic parameters were

The apparent Michaelis constant (Km) for

both control and phenobarbital pretreated mice microsomes was 2.6 x
10 -5 M. The maximum velocity (V max ) for microsomes from control mice
_2
was 1.1 x 10 nmoles/mg protein/minute while that for microsomes from
_2
phenobarbi tal pretreated mice was 1.7 x 10 nmoles/mg protein/
minute.

Phenobarbi tal pretreatment increased the rate of binding by

almost 55% without changing the apparent 14n.
Due to the possible lability of tritiun on the PQ molecule, we
also used 14 C-PQ in some binding studies, In Tables 3 and 4 the
binding of ^H-PQ is compared to that of 14 C-PQ by control and pheno
barbi tal-pretreated microsomes and also by microsomes in the presence
of SK&F-525A or metyrapone.

The binding was somewhat less, but not
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significant, with ^H-PQ than with 14 C-PQ except for the net binding in
the presence of metyrapone; however the results were qualitatively
very similar.

Since the supply of ^C-PQ was quite limited it was

necessary to use

3

H-PQ for most of the studies.

Piperonyl butoxide (PPB), another inhibitor of mi crosomal-drug
metabolizing enzymes, also markedly inhibited the covalent binding of
3
H-PQ to mouse liver microsomal protein when it was added to the
incubation mixture, as shown in Table 5. However,’ the j_n vitro
3
covalent binding of H-PQ to microsomes prepared from piperonyl
butoxide (1360 mg/Kg, i.p.) or SK&F-525A (50 mg/Kg, i.p.) pretreated
mice was only inhibited by 14% (Table 6) although there was a somewhat
greater percentage decrease in cytochrome P450.
The effect of the sulfhydryl-containing compounds, cysteine and
3
glutathione, at a concentration of 1 mM, on covalent binding of H-PQ
metabolites to mouse liver microsomal protein was also studied, with
the results shown in Table 7.

In these studies, covalent binding was

measured in either the presence or the absence of G6PD in the cofactor
mixture.

Glutathione decreased the binding in the absence of G6PD but

cysteine was without significant effect.

In the presence of G6PD

extensive binding occurred in the controls but both reagents inhibited
the net covalent binding almost completely.
As shown in. Tables 8 and 9, it was possible to demonstrate bind3
ing of H-PQ to microsomal protein i n vivo, When SK&F-525A or
piperonyl butoxide was administered to mice intraperitoneally before
3
the H-PQ injection, there was no significant difference in covalent
binding i n vi vo between controls and the pretreated mice.

These doses
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of SK&F-525A and piperonyl butoxide dramatically prolonged hexobarbital sleeping time in the mice indicating that these compounds indeed
3
inhibited drug metabolism. Apparently the covalent binding of H-PQ
in vivo may not involve metabolism.
Figure 6 shows a linear relationship between the dose of
and its in vivo covalent binding to mouse liver microsomes.
of 10 mg/Kg,

14

3

H-PQ

At a dose

C-PQ also bound covalently to microsomes to an extent

similar to that seen with the tritiated isotope.
vi vo covalent binding of

14

However, the in

C-PQ to microsomes of phenobarbital pre

treated mice was significantly less than that to microsomes of control
mi ce.

In preliminary studies a similar phenomenon also occurred with

different doses of ^H-PQ (data not shown).

Apparently increased

metabolism of PQ in vi vo may decrease covalent binding.
The possibility that reactive metabolites of PQ may oxidize GSH
i n vi vo was examined by measuring the reduced glutathione content of
mouse liver and erythrocytes after injection of 80 mg/Kg of PQ.
Figure 7 shows that hepatic GSH was significantly depleted at 60
minutes after the time of injection; the normal level of GSH was regained at 4 hours after primaquine administration.

The GSH content of

erythrocytes was more markedly decreased than that of the liver after
60 minutes and took 8 hours to return to normal after the primaquine
injection, as shown in Figure 8.

Discussion
In terms of criteria used by previous investigators (JoHow et
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al., 1973; Mitchell et al. , 1973a, b; Potter et al., 1973), the data
in Tables 1 and 2 and Figures 1 and 6 clearly show covalent binding of
PQ to microsomal protein both in vitro and in vivo,

The failure of

the pre-extraction with hexane (Table 1) to decrease the binding found
after extraction with methanol appears to rule out the possibility that
3
significant amounts of the bound radioactivity are due to H-PQ
dissolved in the lipids of the microsomes.

At a concentration of 0.01

mM PQ, the net binding of radioactivity due to the presence of the
NADPH-generating system accounts for over 80% of the total binding, at
least for the first 90 minutes of the incubation (Figure 1).

Conver

sion of PQ to reactive metabolites by the mixed function oxidase system
is the most obvious interpretation of this result,

At higher concen-

trations the net binding attributable to the presence of the NADPHgenerating system decreased (Table 2); since PQ itself is relatively
unreactive, nonenzymatic breakdown of PQ to reactive products probably
accounts for the binding seen in the controls without cofactors.
The marked increase in covalent binding in vi tro to microsomes
prepared from mice pretreated with phenobarbital and containing
increased levels of cytochrome P450 (Table 3, Figures 4 and 5) also
clearly points to the role of metabolite(s) in the covalent binding
(Mitchell et ai]_. , 1973a, b; Potter et _al_. , 1973).

The marked decrease

of the net covalent binding produced by the addition of the mixed func
tion oxidase inhibitors, SK&F-525A, metyrapone, and piperonyl butoxide
(Mitchell et_ aj_. , 1973b) shown in Tables 4 and 5 and Figure 4, again
supports the interpretation that metabolites play a major role in the
process of covalent binding in vitro at low concentrations (0.01 mM)
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of PQ.
In contrast to the increased covalent binding seen in vitro,
phenobarbital pretreatment decreased covalent binding of PQ in vivo
(Figure 6).

McLean and Marshall (1971) reported that phenobarbital

diminished rather than increased the carcinogenic effects of aflatoxin
in rats.

Benedict et aj_. (1973) suggested that it is possible that

low levels of microsomal enzymes are sufficient for drug metabolism,
whereas enhanced drug metabolism by inducers of drug metabolism
enzymes may further convert some metabolites to inert derivatives.
Another microsomal enzyme inducer, 3-methylcholanthrene (3-MC), has
been found to potentiate acetaminophen-induced hepatic necrosis
(Mitchell et aj_. , 1973a, b) but protect against carbon tetrachlorideinduced (Suarez et ah , 1971) and bromobenzene-i nduced (Reid et al.,
1971) hepatic necrosis.

It is probable that besides inducing meta

bolic enzymes to produce more reactive metabolites and thus enhance
toxicities, these inducers stimulate an alternate pathway of metabolism
which may compete with the toxic route, or a detoxification one (such
as conjugation) to convert the toxic metabolites to innocuous deriva
tives.

Such events may also account for our results with PQ in vivo.

Again, in contrast to the i n vitro results (Tables 4 and 5,
Figure 4), the effect of the inhibitors, SK&F-525A and PPB, on covalent
binding in vivo was not significant (Tables 8 and 9) even though the
cytochrome P450 mixed function oxidase was indeed inhibited, as shown
by the prolongation of hexobarbital sleeping time.

It is possible

that the level of enzyme activity remaining i n vivo in the presence of
inhibitors is sufficient to produce the relatively lower levels of
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covalent binding found in vivo.

Also other in vivo detoxification

pathway(s) may be inhibited, thus increasing the supply of reactive
metabolite(s) of PQ which bind to microsomal protein.

Alternatively,

the binding in vivo in the presence of the inhibitors may be due to
reactive products formed from PQ by nonenzymatic processes.
Our data show that cysteine and glutathione almost completely
inhibited the covalent binding of PQ metabolite(s) to mouse hepatic
microsomal protein in vitro (Table 7).

Thiol groups such as those of

GSH can combine with reactive metabolites to form S-alkyl or S-aryl
derivatives (Waley, 1966) thus protecting the thiol groups on tissue
proteins against covalent binding.

Administration of PQ to mice

depleted liver and erythrocyte GSH levels (Figures 7 and 8) as would
be expected if reactive metabolites are produced in vivo and react
with the GSH.

This correlates well with the report by Fraser and

Vesell (1968) that the GSH content of G6PD-deficient erythrocytes can
be decreased by incubation with model metabolites of pentaquine.

The

time course of covalent binding to microsomes in vitro and depletion of
GSH in vivo show interesting parallels (cf. Figures 1 and 7); studies
of the time course of covalent binding in vivo would be needed to
establish this relationship more closely.

These results parallel

those of other investigators who have shown that sulfhydryl-containing
compounds such as glutathione and cysteine prevent the arylation of
hepatic macromolecules by toxic metabolites of acetaminophen in vitro
and in vivo without inhibiting the metabolism of the drug (Jollow et
al. , 1973; Mitchell et et. , 1973b; Tredger et_ aj_. , 1981),

Further

more, pretreatments that affected acetaminophen-induced hepatic
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toxicity also altered the depletion of hepatic glutathione (Mitchell
et al. , 1973b).

Olson et ail_. (1980) have shown that doxorubicin, a

potent anti cancer drug, depleted GSH levels in mouse liver, erythro
cytes and heart but induced only dose-dependent cardiotoxicity.
Even though our data indicate that PQ metabolite(s) and/or break
down products can covalently bind to mouse liver microsomal protein
i n vivo as well as i n vitro, we are not aware of any evidence of
hepatic damage following administration of PQ.

As suggested by

Mitchell et aj_. (1975), many drugs can be converted to active metabo
lites and become covalently bound to microsomal protein, but yet this
fact does not necessarily predict the occurrence of toxi city i n vivo.
However, we (Chau et al_. , 1983) have found that reactive products
from PQ may covalently bind to erythrocytes, their membranes and
hemoglobin, thus suggesting that covalent binding of such products could
damage erythrocytes and thus play a role in PQ-induced hemolytic anemia
in G6PD-defi ci ent individuals.
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Table 1.

Covalent binding of 0.01 mM

3

H-primaquine to mouse liver

microsomes in vitro by extraction with hexane and 80% methanol or with
80% methanol alone
nmoles bound/mg protein/60 minutes5

Extraction with

No Co factors

With Cofactors

Net Bound

Hexane and 80%
methanol

0.04 ± 0.003

0.20 ± 0.01

0.16 ± 0.01

80% methanol

0.04 ± 0.003

0.21 ± 0.03

0.17 ± 0.03

aValues shown are the mean and standard error of 3 to 4 experiments.
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Table 2.

Covalent binding of 0.001 mM to 1 mM ^H-primaqui ne (^H-PQ)

to mouse liver microsomal protein in vitro with or without cofactors
nmoles bound/mg protein/30 minutes9
^H-PQ Concen.

No Cofactors

With Cofactors

Net Bound

1 mM

1.98 ± 0.22

2.11 ± 0.13

0.14 ± 0.14 •

0.1 mM

0.23 ± 0.03

0.55 ± 0.08b

0.37 ± 0.06

0.01 mM

0.03 ± 0.001

0.13 ± 0.002c

0.09 ± 0.003

0.001 mM

0.01 ± 0.0003

0.03 ± 0.003c

0.02 ± 0.003

Values shown are the mean and standard error of 3 to 5 experiments.
^Significantly different from the binding without cofactors at
p < 0.010.
Significantly different from the binding without cofactors at
p < 0.005.

Table 3.

Covalent binding of 0.01 mM radiolabeled primaquine to control and pheno-

barbital pretreated mouse liver microsomal protei n i n vitro
nmoles bound/mg protein/30 minutes5
No Cofactors

With Cofactors

Net Bound

0.03 ± 0.001

0.13 ± 0.002

0.09 ± 0.003

C-PQ

0.05 ± 0.01

0.16 ± 0.01

0.11 ± 0.01

Phenobarbital^

3H-PQ

0.04 ± 0.001

0.19 ± 0.01

0.15 ± 0.01c

Phenobarbi tal^

14 C-PQ

0.04 ± 0.02

0.24 ± 0.01

0.20 ± 0.02c

Pretreatment
Control
Control

Form of PQ

3H-PQ
14

Values shown are the mean and standard error of 3 to 4 experiments.
^Mi ce received 60 mg/Kg of phenobarbi tal twice daily for 3 days and were sacrificed
24 hours after the last dose. The cytochrome P450 content of control mice liver
microsomes was 0.76 ± 0.004; of phenobarbital pretreated mice liver microsomes was
1.58 ± 0.12 nmoles/mg protein.
Significantly different from control at p < 0.005.

CO
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Table 4.

Effect of 0.1 mM SK&F-525A and 1 mM metyrapone (MIR) on covalent binding of

0.01 mM primaquine (PQ) to mouse liver microsomal protein in vitro
nmoles bound/mg protein/30 minutes3
Net Bound

%
Inhi bi tion

No Co factors

With Cofactors

0.03 ± 0.001

0.13 ± 0.002

0.09 ± 0.03

C-PQ

0.05 ± 0.01

0.16 ± 0.01

0.11 ± 0.01

SK&F-525A

3H-PQ

0.02 ± 0.001

0.03 ± 0.002

0.01 ± 0.001b

91%

SK&F-525A

14 C-PQ

0.04 ± 0.01

0.05 ± 0.01

0.01 ± 0.003b

92%

MTP

3H-PQ

0.07 ± 0.01

0.08 ± 0.03

0.02 ± 0.02b

83%

MTP

14 C-PQ

0.09 ± 0.01

0.09 ± 0.01

0.002 ± 0.001b

98%

Drug
Control
Control

Form of PQ

3h-pq
14

aValues shown are the mean and standard error of 3 to 5 experiments.
^Significantly different from control at p < 0.001

CO
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Table 5.

Effect of piperonyl butoxide (PPB) at 0.5 mM and 1 mM on covalent bind-

ing of 0.01 mM

H-primaquine to mouse liver microsomal protei n i n vitro
nmoles bound/mg protein/30 minutes9
1o

Net Bound

Inhi bi ti on

Drug

No Cofactors

With Cofactors

Control

0.05 ± 0.003

0.11 ± 0.002

0.06 ± 0.002

PPB, 0.5 mM

0.02 ± 0.001

0.04 ± 0.002

0.01 ± 0.001b

80%

PPB, 1 mM

0.02 ± 0.001

0.03 ± 0.001

0.01 ± 0.002b

83%

aValues shown are the mean and standard error of 3 experiments.
^Significantly different from control at p < 0.001

CO
CO

Table 6.

Effects of pretreatments on covalent binding of 0.01 mM

3

H-primaquine to mouse

liver microsomal protein in vitro
nmoles bound/mg protein/30 minutes3
With Cofactors

Net Bound

0.07 ± 0.01

0.14 ± 0.02

0.07 ± 0.01

SK&F-525A pretreated0

0.07 ± 0.01

0.13 ± 0.01

0.06 ± 0.01

Corn oi 1 pretreated^

0.05 ± 0.004

0.15 ± 0.01

0.10 ± 0.01

Piperonyl butoxide
pretreatede

0.03 ± 0.002

0.12 ± 0.01

0.09 ± 0.02

Source of Microsomes

No Co factors

Normal saline pretreated^

t
Inhi bi tion

14%

14%

aValues shown are the mean and standard error of 3 to 5 experiments.
^Control mice received 0.01 ml/gm of 0.9% NaCl (i.p.) 40 minutes before sacrifice.
P450 content was 0.7 9 ± 0.02 nmole/mg protein.

Cytochrome

CSK&F-525A pretreated mice received 50 mg/Kg of SK&F-525A in 0.9% NaCl (i.p.) 40 minutes
before sacrifice. Cytochrome P450 content was 0.67 ± 0.04 nmole/mg protein.
^Control mice received 0.01 ml/gm of corn oil (i.p.) 30 minutes before sacrifice.

Cyrochrome

P450 content was 0.84 ± 0.07 nmole/mg protein.
ePiperonyl butoxide pretreated mice received 1,360 mg/Kg of PPB in corn oil (i.p.) 30 minutes
before sacrifice. P450 content was 0.5 9 ± 0.08 nmole/mg protein.

CO

-p*

Table 7.

Effect of sulhydryl-contai ni ng compounds on covalent binding of 0.01 mM

3

H-primaquine to

mouse liver microsomal protein in vitro
nmoles bound/mg protein/30 minutes^

l
Drug

Cofactors Without G6PD

Cofactors With G6PD

Net Bound

Inhi bi tion

Control

0.06 ± 0.01

0.21 ± 0.02

0.15

± 0.02

Cysteine, 1 mM

0.07 ± 0.02

0.07 ± 0.02

0.001 ± 0.002c

99%

Glutathione, 1 mM

0.03 ± 0.003

0.05 ± 0.04

0.02

88%

± 0.001d

aThe cofactors were added to the incubation mixture 5 minutes after incubation started.
^Values shown are the mean and standard error of 3 experiments.
Significantly different from control at p < 0.001
dSignificantly different from control at p < 0.05

CO

cn
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Table 8.

Effect of SK&F-525A on covalent binding of ^H-primaqui ne

(80 mg/Kg) to mouse liver microsomal protein in vivo
Pretreatment
Controlb
SK&F-525A

nmoles bound/mg protein9
0.06 ± 0.01

c,d

0.04 ± 0.01

aValues shown are the mean and standard error of 3 experiments.
^Control mice received 0.01 ml/gm of 0.9% NaCl 40 minutes before
3H-primaquine (80 mg/Kg) was injected and the mice were sacrificed 60
minutes after PQ injection. The cytochrome P450 content was 0.85 ± 0.03
nmole/mg protein.
CSK&F-525A pretreated mice received 50 mg/Kg of SK&F-525A in 0.9% NaCl
40 minutes before ^H-primaquine (80 mg/Kg) was injected and the mice
were sacrificed 60 minutes after PQ injection. The cytochrome P450
content was 0.86 ± 0.02 nmole/mg protein.
^Hexobarbital sleeping time of SK&F-525A pretreated mice was significant
ly longer than that of control at p < 0.001. Control mice slept
43.0 ± 5.9 minutes and SK&F-525A pretreated mice slept over 24 hours.
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Table 9. Effect of piperonyl butoxide (PPB) on covalent binding of
3
H-primaquine (80 mg/Kg) to mouse liver microsomal protein in vivo
Pretreatment

nmoles bound/mg protein5

Control*3

0.06 ± 0.01

PPB c,d

0.07 ± 0.004

aValues shown are the mean and standard error of 3 experiments.
^Control mice received 0.01 ml/gm of corn oil (i.p.) for 30 minutes
before ^H-primaquine (80 mg/Kg) was injected and was sacrificed 60
minutes after PQ injection. The cytochrome P450 content was 0.83 ± 0.07
nmole/mg protein.
cPiperonyl butoxide pretreated mice received 1,360 mg/Kg of PPB in corn
oil 30 minutes before ^H-primaquine (80 mg/Kg) was injected and was
sacrificed 60 minutes after PQ injection. The cytochrome P450 content
was 0.24 ± 0.09 nmole/mg protein.
-i

Hexobarbital sleeping time of PPB treated mice was significantly longer
than that of control at p < 0.001. Control mice slept 11.0 ± 2.5
minutes and PPB pretreated mice slept 138.8 ± 13.6 minutes.
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Fi gure 1. Time course of covalent binding of 0.01 mM 3 H-primaquine to
mouse liver microsomes. Each point is the mean and standard error of
#, binding with cofactors; ■
■ , bind3 to 6 experiments. •
ing without cofactors. (Each point is significantly different from
binding with cofactors at the same incubation interval at p < 0.005.)
o
o, net binding.
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3
Fi gure 3. Covalent binding of different concentrations of H-primaquine
to mouse liver microsomal protein in vitro, Each point is the mean and
standard error of 3 to 5 experiments. •——#, binding with cofactors;
■--------a, binding without cofactors; O------ O, net binding.
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Figure 4. Effects of cytochrome P450 inducer and inhibitors on net
covalent binding of 0.005 mM to 0.05 mM ^H-primaquine to mouse liver
microsomal protein in vitro. Each point is the mean and standard error
of 3 to 5 experiments. O----- O, net binding to microsomes from control
mi ce;#
#, net binding to microsomes from phenobarbital pretreated
mi ce;Q
□ , net binding to microsomes from control mice in the
presence of 0.1 mM SK&F-525A;B
■, net binding to microsomes from
control mice in the presence of 1 mM metyrapone.
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Figy re 5. Lineweaver-Burk plot of covalent binding of 0.005 mM to 0.05
mM ^H-primaquine metabolites to control and phenobarbital pretreated
mouse liver microsomal protein in vitro. Each point is the mean and
standard error of 3 to 5 experiments,
#, net binding to microsomes
from control mice, Vmax =1.1 x 10~2 nmoles/mg protein/minute. 0, net
binding to microsomes from phenobarbital pretreated mice, Vmax =1.7 x
10“2 nmoles/mg protein/minute. Apparent ttn =2.6 x 10”^^ for both types
of microsomes.
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3
Figure 6. Covalent binding of H-primaquine (10 mg/Kg to 80 mg/Kg) and
l^C-primaquine (10 mg/Kg) to control and phenobarbital pretreated mouse
liver microsomes in vivo. Control mice: cytochrome P450 content was
0.76 ± 0.004 nmoles/mg protein, •^H-primaquine injected, n=3; A, l^Cprimaquine injected, n=4. Phenobarbi tal pretreated mice (as described
in "Methods") cytochrome P450 content was 1.81 ± 0.05 nmoles/mg protein,
A, l^C-primaquine injected, n=2.
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Figure 7. Effect of 80 mg/Kg of primaquine on reduced glutathione
(GSH) content of mouse liver in vivo. Each point is mean and standard
error for 4 animals.
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Figure 8. Effect of 80 mg/Kg of primaquine on reduced glutathione (GSH)
content of mouse erythrocytes in vivo. Each point is mean and standard
error for 4 animals. •----------•, °l° control of GSH content.
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CHAPTER 3:

COVALENT BINDING AND OTHER MECHANISMS OF

PRIMAQUINE TOXICITY IN HUMAN BLOOD
Introduction
It has long been known that when primaquine (PQ, an antimalarial
drug) is administered to sensitive men, an acute hemolytic anemia
develops (Hockwald et aj_. , 1952).

However, the mechanism of this

reaction is still not completely understood (Beutler, 1978).
Lipid peroxidation appears to play a significant role in druginduced membrane damage.

Liver microsomes undergo lipid peroxidative

damage when they are incubated with NADPH.

When erythrocytes were

incubated with this peroxidative system, they hemolyzed (Rodgers et
al., 1977).

Many agents which deplete GSH in isolated hepatocytes

also induce lipid peroxidation (Anundi ejt a1_., 1979).

Doroshow et al.

(1979) and Olson et aj_. (1980) reported that adriamycin decreased
heart, liver and erythrocyte GSH levels and induced toxicity.
Adriamycin treatment in rats inhibited microsomal cytochrome P450 and
other enzymes activity; it also enhanced in vitro lipid peroxidation
of liver microsomes by producing reactive oxygen species through its
redox cycling and oxidized endogenous membrane a-tocopherol (Mimnaugh
et jfl_. , 1981a, b).

The protective roles of a-tocopherol, GSH, and

other enzymatic defenses against radicals and oxidative damages are
discussed by Fridovich (1978) and Chance ed: aj_.

(1979).

Carbon tetrachloride is the best known compound which is con
verted to trichloromethyl radical by microsomal enzyme and induces
toxicogenic events.

This specie binds to protein and lipid covalently
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(Reynolds, 1967) and also initiates peroxidation of membrane lipids
(Recknagel and Glende, 1973).

Other compounds which initiate toxic

events through their radical metabolites are reviewed by Mason (1979)
and Trush et jH.

(1982).

The chain reactions of membrane lipid peroxidation disrupt mem
brane structure integrity, and thus alter membrane-bound enzyme
activities (van Boxten et aj_. , 1979; Wills, 1971), membrane permea
bility (Hogberg et aj^., 1973), and finally increase membrane deformability and induce membrane breakages (Pasquali-Ronchetti et _al_. , 1980).
Various drugs and foreign compounds have been found to be con
verted in the body to chemically reactive metabolites that bind
covalently to tissue macromolecules thereby causing toxicities (Miller
and Miller, 1966; Miller, 1970; Magee and Barnes, 1967; Judah et al. ,
1970; Mitchell et_ al_. , 1975).

The magnitude of covalent binding

parallels the severity of toxicity (Mitchell ejb ll-, 1973a, b; Jollow
et al. , 1973; Potter et aj_. , 1973), and parallels the depletion of GSH
content (Mitchel1 et al., 1973b).
A sharp depletion of the GSH of G6PD-deficient red cells
followed by acute hemolysis occur after administration of PQ to
susceptible subjects (Flanagan et aj_. , 1958).

This phenomenon empha

sizes the importance of erythrocyte GSH for the maintenance of cell
integrity (Fegler, 1952).

Fraser and Vesell (1968a, b) found that

hydroxylated metabolites of PQ, pentaquine, and acetanilid increased
mechanical fragility and methemoglobin content but decreased GSH con
tent in G6PD-deficient human erythrocytes more than that of normal

56
ones.

Studies of Strother jit _al_. (1981 , 1983) also indicated that

model metabolites of PQ, but not PQ itself, increased a dose-related
methemoglobin formation in normal and G6PD-deficient erythrocytes.
These metabolites depleted GSH content of G6PD-deficient red cells,
whereas normal erythrocyte GSH levels were also depleted by high
concentrations of PQ model metabolites.
The importance of membrane sulfhydryl groups for the integrity of
the red blood cells and for the maintenance of cellular enzymes activ
ity have been demonstrated by some investigators (Rapport and Scheuch,
1960; Scheuch et _al_. , 1961).

The destructi bi lity of red cel Is might

be due to the oxidation of their membrane sulfhydryl groups (Jacob and
Jandl, 1962a, b).

Szeinberg and Clejan (1964) reported that the

protein sulfhydryl groups and GSH in whole blood cells of G6PDdeficient individuals were significantly lower than those of normal
subjects.

In contrast, there were no significant differences in the

membrane sulfhydryl groups and GSH contents between the two kinds of
red cells.
Previous work (Chau et al., 1983) has shown that PQ metabolite(s)
depleted hepatic as well as erythrocyte GSH levels and were bound to
mouse liver microsomal protein covalently.

PQ has also been found to

generate reactive oxygen species (Cohen and Hochstein, 1964; Simmerfield and Tudhope, 1978; Fraser et al. , 1975, 1981 ).

It is possible

that PQ toxicity is mediated by lipid peroxidation of red cell
membranes through reactive oxygen species or by covalent binding of
its reactive metabolite(s) to red cell membranes, hemoglobin and other
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proteins after cellular anti oxidative and other defensive mechanisms
are diminished (Bus and Gibson, 1979; Chance et aj_. , 1979).
In the investigation we are reporting here, we have measured the
lipid peroxidation of mice liver microsomes and human erythrocytes as
well as their membranes by PQ and its model metabolites.

Covalent

binding of PQ to human erythrocytes as well as their membranes and
hemoglobin has been studied.

Effects of a-tocopherol on lipid peroxi-

dation, covalent binding and methemoglobin formation are reported.
The effect of PQ and its derivatives on sulfhydryl groups of normal
and G6PD-deficient erythrocyte membranes was also determined.

Materials and Methods
Chemicals
Primaquine diphosphate (PQ) was obtained from Aldrich Chemical
Company, Inc., Milwaukee, WI.

H-PQ, labelled in the ring system, was

purchased from New England Nuclear Corporation, Boston, MA, and recrystallized in the laboratory with unlabelled PQ to obtain a specific
activity of 0.137 mCi/mmol.

The purity was over 90% as determined by

thin layer chromatography (TIC) with methanol-benzene (2:1) on silica
gel (Strother et aj_. , 1981).

The 5-hydroxy-6-demethylprimaquine

hydrobromide (5H6DPQ) was synthesized as described by Allahyari et al.
(1983).

The blue derivative of 5H6DPQ was prepared in the laboratory

by extracting 5H6DPQ.3HBr in IN NaOH with methylene chloride.
extract turned blue upon exposure to sunlight.

The

The blue compound was

purified by TIC and its identity verified by mass spectrophotometry as
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described by Strother et_ aj_. (1983).

Nicotinamide adenine dinucleo-

tide phosphate (NADP), glucose-6-phosphate monosodi un salt (G6P),
glucose-6-phosphate-dehydrogenase (G6PD), glutathione (reduced form),
bovine serum albumin, himan hemoglobin (Type IV), a-tocopherol acid
succinate, 2-thiobarbituric acid and 1,1,3,3-tetraethoxypropane were
obtained from Si gna Chemical Company, St. Louis, MO.

Magnesi un

chloride was purchased from J. T. Baker Chemical Company, Phillipsburg, NJ.

Sephadex G-75 superfine was supplied by Pharmacia Fine

Chemicals, Inc., Piscataway, NJ.

CytoScint scintillation cocktail was

obtained from WestChem, San Diego, CA.

All other chemicals were of

highest purity available.
Preparation of Microsomes
Male Swiss-Webster mice, obtained from Simonsen Laboratories,
Gilroy, CA and weighing 22-27 g, were fed regular Purina Lab Chow and

water ad libitun.

They were killed by cervical dislocation, the

livers were dissected out immediately and the gallbladder and other
extraneous tissue rapidly removed.

The livers were then blotted on

absorbent paper, quickly weighed, and placed in ice-cold 1.15% KC10.025 M Tris buffer, pH 7.35.

A 33% suspension of microsomes, in the

same buffer, was prepared as described by Peters and Strother (1971).
Preparation of 50% Hunan Erythrocyte Suspension and Erythrocyte
Membranes (GhostiJ
Blood specimens were obtained by venipuncture from normal and
G6PD-deficient volunteers with disodium edetate as anticoagulant.
50% washed erythrocyte suspension was prepared in 0.85% buffered

The
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saline containing 10 mM dextrose as described by Fraser and Vesell
(1968a).

Human erythrocyte ghosts were prepared from washed, packed

cells by the method described by Fairbanks et aj_. (1971).
Protein content was measured by the method of Lowry et ah (1951)
using crystalline bovine serin albumin as the reference standard.
Hemoglobin concentration was determined by reading the absorbance (at
540 nm) in cyanmethemoglobin reagent (Hycel Inc., Houston, IX) using
human hemoglobin (Si gna Chemical Co., Type IV) as the reference
standard.
Lipid Peroxidation
Mouse liver microsomes (1.75 mg), human erythrocytes (0.5 ml of
50% RBC suspension), or human erythrocyte membranes (4.0 mg) were
incubated alone or with PQ, 5H6DPQ, or the blue derivative of 5H6DPQ
(at concentrations indicated in "Results") in the presence or absence
of an NADPH-generating system (cofactors) in 0.5 ml 0.25 M Iris buffer
(pH 7.35) containing NADP (3.3 ymol), G6P (35 ymol), MgCl^ (15 ymol),
and G6PD (2 units).

The blue derivative of 5H6DPQ was dissolved in

methanol, placed in the incubation flasks and the methanol was evapo
rated under a stream of

prior to addition of any other materials.

Tris buffer (0.25 M, pH 7.35) was added to bring the final volume of
the incubation mixtures to 1.75 ml.

Incubation was carried out at

37°C under air in a Dubnoff shaking incubator for varying times.

Zero

time blanks containing all the components of the incubation mixtures
were also included.

In some experiments, a-tocopherol was added in a

small volume of absolute alcohol to produce a final concentration of
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0.01 mM.

Lipid peroxidation was quantitated by spectrophotometric

determination of the malondi aldehyde-thiobarbi turic acid complex
(Bernheim et al., 1948).

At the end of the incubation, 0.75 ml of

cold 2.0 M TCA-1.7 M HC1 was added to each incubation flask.

The

incubation mixtures were transferred to centrifuge tubes and centrifuged at 1000 x g for 10 minutes,

To each 0.5 ml of the clear super-

natant, 2.0 ml of 1.0% w/v 2-thiobarbituric acid reagent (Kohn and
Li versedge, 1944) was added and incubated at 95°C for 15 minutes and
cooled on ice.

The absorbance was measured at 533 nm on a Beckman

Acta MVI UV-visible spectrophotometer.

Standard malondialdehyde was

prepared by the acid hydrolysis of tetraethoxy-propane.
Binding to Mouse Liver Microsomal Protein
•3

H-PQ was incubated with mouse liver microsomes, containing

a-tocopherol in absolute ethanol or absolute ethanol, with or without
an NADPH-generating system in 1.0 ml 0.25 M Tris buffer (pH 7.35)
containing NADP (4 ymol), G6P (25 ymol), MgCl^ (30 ymol) and G6PD
(2 units).

The incubation conditions and method of extraction of the

mouse liver microsomal protein were previously described (Chau et al. ,
1983).
Binding to Human Erythrocytes
-3

H-PQ was incubated with 1.0 ml 50% human erythrocytes suspension

and mice liver microsomes (10 mg) in the presence or absence of an
NADPH-generating system as described previously.

After incubation at

37°C for 60 minutes under air in a Dubnoff shaking incubator, the
incubation mixtures were centrifuged at. 500 x g for 10 minutes.

The
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supernatant was aspirated from the erythrocytes as much as possible.
The bottom-most 0.3 ml of the packed erythrocytes was transferred to
13 ml centrifuge tubes and lysed with 0.9 ml of distilled water.
Absolute methanol (3.0 ml) was added to the lysed erythrocytes and the
tubes were centrifuged again at 1000 x g for 10 minutes.

The protein

pellets were extracted 3 times with 2 ml hexane and then 9 times with
80% methanol as previously described (Chau et aj_. , 1983).

The

extracted protein pellet was dissolved in 1.0 ml 10% sodiim dodecyl
sulfate and an aliquot of 20 yl was added to 10.0 ml CytoScint
scintillation cocktail.

Radioactivity was determined in a Beckman LS-

250 scintillation counter.
Binding to Human Erythrocyte Membranes (Ghosts)
o

H-PQ was incubated with human erythrocyte membranes (4.0 mg) and
mouse liver microsomes (10.0 mg) with or without an NADPH-generating
system.

The protein was precipitated by 10% TCA and extracted as

described above.
Binding to Human Hemoglobin
A column (35 x 1.4 cm) of superfine Sephadex G-75 was packed in
equilibriun with 0.05 M phosphate buffer, pH 7.8, containing 0.15 M
NaCl.

Human hemoglobin. Type IV, 100 mg/ml in the same buffer was

reduced by excess sodiim dithionite, added to the column and eluted
with the same buffer.

The main band was collected and stored under
3
(Summerfield and Tudhope, 1978).
H-PQ was incubated for 60 minutes

with the eluted hemoglobin (75 mg) and mouse liver microsomes (10 mg)
in the presence or absence of an NADPH-generating system as described
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above.

The incubation mixtures were transferred to ultracentrifuge

tubes at the end of the incubation.

The tubes were centrifuged at

105,000 x g for 30 minutes in a Beckman Model L3-50 ultracentrifuge.
The microsome free supernatant was placed on the Sephadex G-75 column
and eluted with 0.05 M pH 7.8 phosphate buffer containing 0.15 M NaCl.
The effluent was monitored at 280 nm and fractions were collected.

An

aliquot of 100 ul of each fraction was added to 10 ml CytoScint cock
tail and counted for radioactivity.
Methemoglobin Formation and Assay
PQ, 5H6DPQ and the blue derivative of 5H6DPQ were incubated with
0.5 ml of a 50% normal or G6PD-deficient erythrocyte suspension at
37°C for 60 minutes in a Dubnoff shaking incubator,

Sufficient Tris

buffer (0.25 M, pH 7/35) was added to the incubation mixtures to bring
the final volume to 1.75 ml.

The flasks were placed in ice for 5

minutes at the end of the incubation and the contents then transferred
to centrifuge tubes.
minutes.

The tubes were centrifuged at 1000 x g for 10

The supernatant was aspirated and the packed erythrocytes

were washed twice with 2.0 ml 0.85% buffered saline containing 10 mM
dextrose.

An aliquot of 0.1 ml of the resuspended 50% erythrocytes

suspension in the above buffer was used for methemoglobin assay as
described by Fraser and Vesell (1968a).

In some experiments

a-tocopherol in absolute ethanol was added to the incubation mixture
to study its effects on methemoglobin formation by 5H6DPQ.
Mice were injected with PQ (80 mg/Kg, i.p.) and sacrificed by
cervical dislocation at various times after PQ administration.

Blood

63
was collected by cardiac puncture with heparin as anticoagulant.
blood was centrifuged at 1000 x g for 10 minutes.

The

The packed

erythrocytes were washed with 0.85% buffered saline containing 10 mM
dextrose and methemoglobin assays were performed as described above.
Effects of Primaquine and Its Metabolites on Normal and G6PDDeficient Erythrocyte Membrane Sulfhydryl Levels
PQ, 5H6DPQ, or the blue derivative of 5H6DPQ was incubated with
4.0 ml of normal or G6PD-deficient red blood cells (50% suspension).
A sufficient volume of 0.25 M Tris buffer, pH 7.35 was added to
bring the final volume of incubation mixtures to 5.0 ml.

Incubation

was carried out at 37°C under air for 60 minutes in a Dubnoff shaking

incubator.

Incubation flasks were kept in ice for 5 minutes at the

end of the incubation.

The incubation mixtures were then transferred

to centrifuge tubes and centrifuged at 1000 x g for 10 minutes.

The

supernatant was aspirated and the packed erythrocytes were lysed with
40 ml of cold 4 mM Na phosphate buffer, pH 8.0, and ghosts were
prepared by the method of Fairbanks et al. (1971).

The ghosts were

resuspended in 0.5 ml of 0.02 M disodiun EDTA and a sufficient volume
of the same sodium phosphate buffer up to the original volume of the
packed cells.

An aliquot of the ghost suspension (0.4 ml) was mixed

with 4.55 ml of 0.01 M sodi un phosphate buffer (pH 8.0) and 0.05 ml of
0.01 M DTNB in absolute methanol.

The solution was kept in the dark

at room temperature for 50 minutes and then centrifuged at 17,000 x g
for 5 minutes (Szeinberg and Clejan, 1964).

The absorbance at 412 nm

was measured against both a reagent blank (no tissue) and a tissue

blank (no DTNB).
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Statistics
Data were expressed as the mean ± S.E.M.

The significance of the

difference between means was determined by Student's t-test.

Statis

tical differences were considered to be significant when p < 0.05.

Results
Lipid Peroxidation and Covalent Binding in Microsomes
As expected, Table 10 shows that lipid peroxidation in mouse liver
microsomes was markedly enhanced by the presence of the cofactor
mixture which generated NADPH.

When 0.1 mM PQ was added there was a

marked decrease in lipid peroxidation indicating substrate inhibition
of NADPH-induced microsomal lipid peroxidation as has been reported for
other compounds (Miles et a_]_. , 1980).

The time course of lipid

peroxidation over 60 minutes in the presence of 0.1 mM PQ, 5H6DPQ or
the blue derivative of 5H6DPQ was examined with the results shown in
Figure 9; zero time values were subtracted from those at all other
incubation intervals.

Most of the lipid peroxidation occurred in the

first 15 minutes; following this period the results were quite varia
ble except for a steady increase in lipid peroxidation with 5H6DPQ in
the presence of cofactors.

Overall, 5H6DPQ was the most active in

producing lipid peroxidation while its blue derivative was the least
active; in all cases the effect was greater in the presence of NADPH
generated by the cofactor mixture.
Addition of a-tocopherol (0.01 mM) produced more than a 50%
inhibition of lipid peroxidation in the presence of primaquine and
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cofactors as shown in Table 11.

The results of a comparable study of

the effect of a-tocopherol on the covalent binding of tritiated PQ to
mouse liver microsomal protein are shown in Table 12.

There was a 30%

inhibition of covalent binding when a-tocopherol in absolute alcohol
was added to the incubation mixture in the binding studies, whereas
the inhibition effect contributed by absolute ethanol alone was only
10%.

It appears that a-tocopherol inhibited lipid peroxidation in the

presence of PQ significantly more than it inhibited the covalent bind
ing of PQ.
Lipid Peroxidation in Erythrocytes
As shown in Table 12, considerable lipid peroxidation occurred in
intact erythrocytes incubated for 60 minutes;, addition of the cofactor
mixture produced a small increase in the amount of peroxidation.

When

PQ was added in the absence of cofactors there was much less lipid
peroxidation than in the control; addition of cofactors removed this
inhibitory effect of PQ so that peroxidation was now a little greater
than in the control with cofactors.

Quite similar results were

obtained with 5H6DPQ and the blue derivative from 5H6DPQ, although
they were less inhibitory to lipid peroxidation in the absence of
cofactors.
The results of a study of the time course of lipid peroxidation
in human erythrocyte membranes in the presence of 5H6DPQ and with and
without cofactors are shown in Figure 10.

5H6DPQ significantly

inhibited the NADPH-induced lipid peroxidation in erythrocyte mem
branes in contrast to the lack of such inhibition in intact erythrocytes.
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Methemoglobin (metHb) Formation in Erythrocytes
As reported previously (Strother et _al_. , 1981, 1983), low (0.10.005 mM) concentrations of 5H6DPQ readily oxidize Hb to metHb in both
normal and G6PD-deficient erythrocytes.

A comparison of metHb forma

tion by 0.1 mM PQ, 5H6DPQ and the blue derivative of 5H6DPQ in normal
and G6PD-deficient human erythrocytes after a sixty minute incubation
is shown in Table 14.

5H6DPQ was much more active than PQ or the blue

derivative and produced si gni fi cantly more metHb in G6PD-defi cient
than in normal erythrocytes.

In contrast to its effect on lipid

peroxidation and covalent binding, a-tocopherol did not inhibit met
hemoglobi n formation by 5H6DPQ in normal erythrocytes (Table 15).
Covalent Binding in Erythrocytes
In Table 16 are shown the results of studies on the covalent
binding of 0.01 mM ^H-PQ to total protein of both normal and G6PDdefi cient erythrocytes incubated with mouse liver microsomes with and
without the cofactor mixture present.

There was a significant net

binding attributable to the presence of the cofactors,

Also the net

binding to the protein of G6PD-deficient cells was significantly
greater than that to normal erythrocytes.
The possibility that PQ or its metabolites may bind covalently
to the proteins of erythrocyte membranes was examined by incubating
3
0.01 or 0.1 mM H-PQ with mouse hepatic microsomes and human erythro
cyte membranes in the presence or absence of the cofactor mixture.

It

was not possible to separate the microsomes from the erythrocyte
membranes after the incubation so that it was only possible to measure
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the total covalent binding to the combined microsomal and membrane
protein.

At both concentrations of PQ the net binding to the combined

microsomal-membrane protein (attributable to the presence of cofactors)
was significantly greater than that when PQ was incubated with mouse
liver microsomes alone (Table 17).

These results suggest that there

was small but significant amount of primaquine metabolite(s) bound to
human erythrocyte membrane proteins.
Since covalent binding to membranes could involve -SH groups, the
effect of 0.1 mM PQ, 5H6DPQ or the blue derivative of 5H6DPQ on the
-SH groups of normal and G6PD-defi ci ent erythrocyte membranes was
measured.

Table 18 shows that all three compounds significantly

decreased the amount of measurable sulfhydryl groups of G6PD-deficient
human erythrocyte membranes but had no effect on normal erythrocyte
membranes.

The effect of 5H6DPQ was more marked than that of PQ or

the blue derivative of 5H6DPQ.
The possibility that PQ or its metabolites may bind covalently to
hemoglobin was examined by incubating human hemoglobin (Type IV) with
o

H-PQ and mouse liver microsomes as described under "Methods."

As

shown in Table 19 and Figures 11 and 12, after separation on a Sephadex
G-75-40 column, a significant amount of radioactivity was found in the
fractions from the incubation mixture containing cofactors which was
significantly greater than that from the incubation mixture lacking
cofactors.
be due to

The radioactive peaks B and C of Figures 3 and 4 appear to
3

H-PQ and breakdown products or metabolites of PQ; they were
3
also observed when H-PQ was chromatographed in 0.25 M Tris buffer on
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the Sephadex G-75-40 column without prior incubation,

Also the small

absorbance peak at 280 nm from fractions 35 to 47 in Figure 12 may be
attributable to primaquine metabolite(s) since model metabolites of
primaquine did show some absorbance at that wavelength.
Oxidation of Hemoglobin in vivo
Table 20 shows that there is no significant amount of methemoglobin produced in vivo after injection of 80 mg/Kg of PQ.

Discussion
Although PQ has been found to produce reactive oxygen species
(Cohen and Hochstein, 1964; Summerfield and Tudhope, 1978; Fraser et
al_. , 1981) and the 5 ,6-di hydroxy derivative (5H6DPQ) may react with
oxygen to produce hydrogen peroxide (Fraser ^t al., 1981) they did
not stimulate NADPH-dependent microsomal lipid peroxidation in this
study.

In fact, PQ, 5H6DPQ, and the blue derivative from 5H6DPQ

inhibited NADPH-induced microsomal lipid peroxidation markedly.
Many investigators have reported substrate inhibition of NADPHinduced microsomal lipid peroxidation (Orreni us el: jil_. , 1964; Pederson
and Aust, 1974; Miles, 1980) but suggested different mechanisms.
Orreni us et a/L

(1964) proposed that the inhibition is due to a compe

tition between drug metabolism and lipid peroxidation for reducing
equivalents derived from NADPH.

Pederson and Aust (1974) concluded

that the inhibition of lipid peroxidation is caused by the antioxidant
properties of a drug metabolite which is formed in the presence of
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NADPH.

Miles et_ a]_. (1980) believe that inhibition of hepatic micro

somal lipid peroxidation is independent of drug metabolism but is
caused by the antioxidant properties of the substrates,

PQ is known to

be metabolized rapidly in the body (Tarlov et al_. , 1962) and has oxidant
and redox properties (Flanagan et al_. , 1958; Tarlov et al_., 1962).
It seems likely that the inhibitory effect of PQ and its derivatives
on hepatic microsomal lipid peroxidation is due to the competition
between drug metabolism and lipid peroxidation for NADPH-reduci ng equivalents.
On the other hand, Anundi et aj_. (1979) and Smith et al. (1983)
found that bromobenzene also shows some degree of substrate inhibition
of lipid peroxidation and they suggested that the lipid peroxidation
which occurs during bromobenzene toxicity is due to the depletion of
GSH and is a consequence of cell death.
The small amount of NADPH-induced lipid peroxidation in the
presence of PQ is reduced by a-tocopherol to less than 50%.
a-Tocopherol is a well known antioxidant and radical scavenger,

It

interrupts the free radical chain reactions of lipid peroxidation
(Bus and Gibson, 1979; Chance et aj_., 1979).
The inhibition of covalent binding of PQ metaboli te (s) to mouse
liver microsomal protein by a-tocopherol is probably due to its
antioxidant effect which spared hepatic GSH from oxidation and thus
protect tissue macromolecules against electrophilic attack by PQ
reactive metabolite(s).
Substrate inhibition of NADPH-dependent lipid peroxidation was

70
also found in human erythrocytes and erythrocyte membranes in the
presence of PQ, 5H6DPQ and the blue derivative of 5H6DPQ.

In order to

ensure the presence of sufficient reducing equivalents, an NADPHgenerating system was added to human intact erythrocytes and
erythrocytes membranes in lipid peroxidation studies.

The addition of

cofactors to intact red cells (Table 13) may enhance the redox cycling
reaction between oxyhemoglobin and PQ as well as its derivatives,
increase reactive oxygen species production, and thus potentiate lipid
peroxidation.
5H6DPQ is more active in producing methemoglobin in vitro than PQ
and the blue derivative from 5H6DPQ, especially in G6PD-deficient red
cells as reported by Strother et aj_. (1981, 1983).

This result

indicates that a PQ metabolite(s) is more potent than PQ itself in
inducing toxicity.

G6PD-deficient cells are more vulnerable than

normal cells to oxidative damage.

Even though PQ can deplete hepatic

and erythrocyte GSH contents as reported previously (Chau et al. ,
1983) it does not produce a significant amount of methemoglobi n in
vivo.

In contrast to its effect on lipid peroxidation and covalent

binding, a-tocopherol does not inhibit in vitro methemoglobi n forma
tion by 5H6DPQ in normal red cells.
The fact that PQ metabolite(s) decreased sulfhydryl groups of
G6PD-deficient human erythrocyte membranes significantly but had no
effect on those of normal red cell membranes suggests that covalent
binding may be one of the mechanism of PQ-induced hemolysis,

The

results of other studies in our laboratory (unpublished data) with
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5H6DPQ and its blue derivative, show a dose-related decrease of GSH
contents of G6PD-deficient erythrocytes but not of normal cells.
Flanagal et ail_.

(1958) have also found that an acute destruction of

GSH precedes hemolysis in PQ-sensitive subjects.

Further evidence is

provided by the fact that the PQ metabolite(s) binds to human
erythrocyte total protein, hemoglobin and plasma membrane protein
covalently.
binding.

G6PD-deficient erythrocytes are more prone to covalent

Furthermore, Beutler et aj_.

(1957) and Tarlov et a]_ (1962)

did not find an equivalent rise in oxidized glutathione (GSSG) to the
fall in GSH.

Beutler et _a]_. (1957) suggested that GSSG may change to

hydrogen sulfide eventually, and Tarlov et al_.

(1962) explained that

there may be a formation of mixed sulfides of GSH with sulfhydryl
groups of the globin molecule.

We suggest that the decrease of GSH

may be due to covalent binding in addition to oxidation.
A recent study of Kelman et _al_.

(1982) indicated that PQ lowers

cellular NADPH level but not GSH content, and stimulate the hexose
monophosphate shunt in normal human erythrocytes.

These investigators

agree with Cohen and Hochstein (1964) that PQ mediates H^O^ formation,
in oxyhemoglobin-containing red cells and PQ reacts with NADPH to
produce H^.
In normal red cells, the activity of G6PD is increased by the
decreased NADPH levels, which is either lowered by direct interaction
with PQ (Kelman .et a/L , 1982) or by consimption in glutathione
reductase reactions to reduce GSSG or peroxides (Cohen and Hochstein,
1964), or by the combination of both reactions, and thus glucose-6-
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phosphate is oxidized at a higher rate to regenerate an adequate
amount of NADPH.

In G6PD-deficient erythrocytes, as the hexose

monophosphate pathway activity is diminished, adequate NADPH levels
cannot be maintained under oxidative stress.
The result of this study and others suggest the following sequence
of events leading to PQ induced hemolysis:

(1) Cellular GHS content is

depleted by PQ metabolite(s) and reactive oxygen species produced from
PQ through covalent binding, conjugation, or oxidation,

(2) The G6PD-

deficient erythrocytes are incapable of maintaining an adequate amount
of NADPH for the reduction of GSSG and mixed disulfide of GSH and
protein to regenerate GSH by way of the glutathione reductase reaction.
GSH is important in maintaining the sulfhydryl groups of red cell
enzymes and membranes in the reduced state (Beutler, 1978), and in
removing the harmful hydrogen peroxide and organic peroxides in erythro
cytes.

The GSH depletion renders the red cell membranes susceptible to

oxidative change and red cell enzymes to inactivation.

(3) PQ

metabolite(s) oxidize(s) and binds to vital red cell membrane proteins,
hemoglobin, and enzymes after the protective role of GSH is decreased.
(4) Red cell membrane permeability is then changed (Weed, 1961), enzyme
functions are altered or destroyed and eventually the lysis of erythro
cytes occurs (Beutler, 1954).
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Table 10.

Effect of 0.1 mM primaquine (PQ) and cofactors (CM) on lipid

peroxidation in mouse hepatic microsomes
nmoles malondialdehyde
equivalent/mg microsomal protein5
60 minutes

60 mi n-0 mi n.

Condition

0 minutes

Microsome

0.78 ± 0.20

7.00 ± 0.79

6.22 ± 0.65

Microsome + CM

0.85 ± 0.03

52.17 ± 6.50

51.33 ± 6.50b

Microsome + PQ

0.79 ± 0.08

2.41 ± 0.19

1.62 ± 0.35

Microsome + PQ + CM

0.79 ± 0.06

2.88 ± 0.33

2.11 ± 0.35c

aValues shown are means and standard errors for 3 to 7 experiments.
bSi gnificantly different from microsome incubated without CM at

p < 0.001
Significantly different from microsome incubated with CM at

p < 0.001
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Table 11.

Effect of 0.01 mM a-tocopherol on lipid peroxidation in mouse

liver microsomes by 0.01 mM primaquine (PQ) in the presence or absence
of cofactors (CM)
nmoles malondialdehyde equivalent/mg
microsomal protein5
Drug

No Cofactors

With Cofactors

PQ (control)

0.94 ± 0.26

8.06 ± 0.37

PQ + a-tocopherol in absolute
ethanol

0.53 ± 0.17

3.44 ± 0.65b

PQ + absolute ethanol

1.18 ± 0.35

9.80 ± 0. 48C

aValues shown are means and standard errors for 4 experiments. Zero
time values was subtracted from values at 60 minutes of incubation.
^Significantly different from control with CM at p < 0.005
Significantly different from control with CM at p < 0.025

Table 12.

Effect of 0.01 mM a-tocopherol on covalent binding of 0.01 mM

3

3
H-primaquine ( H-PQ) to

mouse liver microsomal protein in vitro in the presence or absence of cofactors
nmoles bound/mg protein/60 minutes5
Drug

No Cofactors

With Cofactors

^H-PQ (control)

0.05 ± 0.01

0.26 ± 0.001

0.21 ± 0.01

H-PQ + a-tocopherol in
absolute ethanol

0.04 ± 0.004

0.19 ± 0.01

0.15 ± 0.01b

30%

^H-PQ + absolute ethanol

0.04 ± 0.004

0.24 ± 0.004

0.19 ± 0.003c

10%

3

Net Bound

% Inhibition

Values shown are means and standard errors for 3 to 4 experiments.
bSignificantly different from control at p < 0.005
Significantly different from control at p < 0.025

---j

<_n
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Table 13. Lipid peroxidation of human erythrocytes by primaquine
and its model metabolites
nmoles malondialdehyde equivalent/qm Hba
Drug

No Cofactors

With Cofactors

None (control)

50.8 ± 17.4

74.0 ± 11.5

0.1 mM PQ

21.9 ±

5.0

84.1 ± 31.2

0.1 mM 5H6DPQ

39.7 ± 15.6

79.4 ± 27.0

0.1 mM blue compound from
5H6DPQ

36.5 ±

91.4 ±

9.3

8.3

aValues shown are means and standard errors for 4 experiments. Zero
time values were subtracted from values at 60 minutes of incubation.
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Table 14.

Effect of 0.1 mM primaquine, 5H6DPQ and blue compound

from 5H6DPQ on methemoglobin formation of normal and G6PD-deficient
erythrocytes i_n vitro
Percent methemoglobina
Drug

Normal RBC

G6PD deficient RBC

None (control)

3.0 ± 0.9

2.1 ± 0.7

PQ

1.7 ± 0.4

3.4 ± 0. 6b

14.2 ± 0.7

24.8 ± 2.0C

5H6DPQ
Blue compound from
5H6DPQ

5.7 ± 0.8

5.6 ± 0.8

aValues shown are means and standard errors for 4 experiments.
^Significantly different from normal RBC at p < 0.05
Significantly different from normal RBC at p < 0.005
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Table 15. Effect of 0.01 mM a-tocopherol on methemoglobin
formation by 0.1 mM 5H6DPQ in vitro
Drug
None (control)

Percent methemoglobina
2.2 ± 0.4

5H6DPQ

12.4 ± 0.8b

5H6DPQ + a-tocopherol in
absolute ethanol

13.5 ± 0.6b

5H6DPQ + absolute ethanol

12.0 ± 1.0b

aValues shown are means and standard errors for 4 experi
ments.
^Significantly different from control at p < 0.001
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Table 16. Covalent binding of 0.01 mM

3

H-primaquine to normal and

G6PD-deficient human erythrocyte protein in vitro
pmoles bound/mg human RBC protein5
No Cofactors

With Cofactors

Net Bound

Normal

7.1 ± 2.2

12.3 ± 2.3

5.2 ± 0.5

G6PD-defi ci ent

8.6 ± 0.7

17.6 ± 2.6

9.0 ± 1.9b

RBC

aValues shown are means and standard errors for 3 to 4 experiments.
bSignificantly different from normal RBC at p < 0.05

Table 17.

Covalent binding of

3

H-Primaquine to mouse liver microsomal protein and hunan

erythrocyte membrane j_n vi tro
nmoles bound/mg microsomal protein/4 mg RBC membrane3
3H-PQ Cone.

No Cofactors

With Cofactors

Net Bound

Microsome (control)

0.1 mM

0.50 ± 0.03

1.07 ± 0.06

0.57 ± 0.03

Microsome + RBC membrane

0.1 mM

0.46 ± 0.02

1.15 ± 0.02

0.69 ± 0.04b

Microsome (control)

0.01 mM

0.05 ± 0.01

0.20 ± 0.001

0.16 ± 0.01

Microsome + RBC membrane

0.01 mM

0.05 ± 0.003

0.25 ± 0.01

0.20 ± 0.02c

Condi ti on

aValues shown are means and standard errors for 3 to 4 experiments.
^Significantly different from control (0.1 mM) at p < 0.05
cSignificantly different from control (0.01 mM) at p < 0.05

oo
o

Table 18. Effect of 0.1 mM primaquine, 5H6DPQ, and blue compound from 5H6DPQ on
sulfhydryl groups of normal and G6PD-deficient human erythrocyte membrane in vitro
-SH groups, mg/gm human RBC membrane protein
G6PD-defi cient RBC

Normal RBC Membrane

membrane

I Normal

None (control)

13.3 ± 1.0

9.7 ± 1.6

75%

PQ

12.1 ± 0.9

8.3 ± 1.5b

69%

5H6DPQ

12.8 ± 1.2

6. 9 ± 0. 9C

54%

Blue compound from 5H6DPQ

12.2 ± 0.8

8.1 ± 1.6d

66%

Drug

aValues shown are means and standard errors for 4 to 5 experiments.
Significantly different

from normal at

p < 0.05

Significantly different

from normal at

p < 0.001

^Significantly different

from normal at

p < 0.05

00
1—*
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Table 19.

Covalent binding of 0.01 mM

3

H-primaquine

to human hemoglobin (Type IV) in vitro
nmoles bound/mg hemoglobin/30 minutes5

No Cofactors

With Cofactors

Net Bound

0.038 ± 0.006

0.062 ± 0.003b

0.024 ± 0.003

aValues shown are means and standard errors for 3
experiments.
Significantly different from binding without cofactors
at p < 0.025
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Table 20.

Effect of 80 mg/Kg of primaquine on methemo-

globin formation in vivo
Hours after PQ injection

Percent methemoglobina

0

1.6 ± 0.5

0.5

3.6 ± 0.1

1

0.9 ± 0.3

2

2.2 ± 0.5

4

1.1 ± 0.1

8

2.7 ± 0.1

aValues shown are the mean and standard error for 4 animals.

84

Figure 9. Time course of effect of 0.1 mM primaquine, 5H6DPQ, and blue
compound from 5H6DPQ on lipid peroxidation of mouse liver microsomes in
vitro. Each point is mean and standard error for 3 to 6 experiments.
A'
A, primaquine; ▲—
A, primaquine + CM; □
□ , 5H6DPQ;
-■ , 5H6DPQ + CM; o
—o, blue compound from 5H6DPQ;
t, blue compound from 5H6DPQ + CM.
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Figure 10. Time course of lipid peroxidation of human erythrocyte
membrane. Each point is mean and standard error of 3 experiments.
0
RBC membrane + CM;
0, RBC membrane; »
□, RBC membrane + 0.1 mM 5H6DPQ; ■■
□
■* , RBC membrane
+ 0.1 mM 5H6DPQ + CM. *Significantly different from RBC membrane +
CM at p < 0.025.
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Figure 11. Column chromatography of human hemoglobin (Type IV) on
Sephadex G-75-40 gel after incubated with 0.01 mM ^H-primaquine and
mouse liver microsomes i_n vitro. All fractions were counted for radioactivity.
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Figure 12. Column chromatography of human hemoglobin (Type IV) on
Sephadex G-75-40 gel after incubated with 0.01 mM ^H-primaquine, mouse
liver microsomes, and cofactors in vitro. All fractions were counted
for radioactivity. --------- s ^280’ *---------- radioactivity in dpm.
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